Neoadjuvant Durvalumab Combination Misses Mark in EGFR+ NSCLC
Patients with EGFR-mutated non–small cell lung cancer had a median event-free survival of 30.8 months in the durvalumab arm and 19.6 months in the placebo arm.
Benmelstobart Plus Anlotinib Shows Survival Benefit in ES-SCLC
The benmelstobart combination reduced the risk of death by 39% vs placebo plus chemotherapy in patients with extensive-stage small cell lung cancer.
Durvalumab Garners Similar OS, Albeit Varied PFS, Outcomes in EGFR+ and EGFR-Wildtype NSCLC Subgroups
Findings from the PACIFIC-R trial showed that patients with EGFR-mutated non-small cell lung cancer experienced shorter progression-free survival with durvalumab than patients with EGFR-wildtype disease.
Repotrectinib Showcases Early Intracranial Responses in Select ROS1+ NSCLC
The confirmed objective response rate with repotrectinib was 79% among tyrosine kinase inhibitor (TKI)-naïve patients and 38% among TKI-pretreated patients.
Osimertinib May Be More Effective in Frontline EGFR+ NSCLC When Combined With Chemo
The median progression-free survival was 25.5 months with osimertinib plus chemotherapy and 16.7 months with osimertinib alone.
Sacituzumab Govitecan/Pembrolizumab Shows Early Antitumor Activity in Metastatic NSCLC
The objective response rate with sacituzumab govitecan plus pembrolizumab was 56%.
Patritumab Deruxtecan Elicits Durable Responses in Pretreated EGFR-Mutated NSCLC
Patrimumab deruxtecan garnered a 29.8% overall response rate in pretreated patients with EGFR-mutated non–small cell lung cancer.
2-Year Follow-Up Supports Adagrasib Monotherapy in KRAS G12C–Mutant NSCLC
Adagrasib elicited a 1-year overall survival rate of 52.8% and 2-year rate of 31.3%.
Iruplinalkib Produces Longer PFS Than Crizotinib in Advanced ALK+ NSCLC
The median progression-free survival with iruplinalkib was 27.70 months vs 14.62 months with crizotinib.
Integration of Sexual Health Considerations Into Thoracic Oncology Care Is Critical
Findings from the SHAWL study found that sexual dysfunction rates are high among women with lung cancer.
Experimental Dosing Strategy With Sotorasib Plus Immunotherapy Helps Combat Hepatotoxicity in KRAS G12C+ NSCLC
Sotorasib is often associated with a high rate of hepatotoxic events, most of which are from elevated liver enzymes. However, a lead-in dosing strategy may help address this adverse event and improve patient tolerability.
NSCLC Survivors Highlight Unmet Needs in Long-Term Experiences With Immunotherapy
A study presented at the 2022 World Conference on Lung Cancer explored the experiences of patients who received checkpoint inhibition therapy for non–small cell lung cancer.
3.5-Year Follow-Up Finds Pembrolizumab/Etoposide Combo Still Effective in Untreated ES-SCLC
Patients with treatment-naive extensive-stage small cell lung cancer showed encouraging clinical responses with pembrolizumab and etoposide after multiple years of follow-up.
Atezolizumab Signals OS Improvement in Patients with Resected NSCLC
Phase 3 findings from the IMpower010 trial show that patients with resected non–small cell lung cancer may achieve an overall survival benefit with atezolizumab.
Larotrectinib Holds Ground as Effective Treatment in NTRK-Positive Lung Cancer
Extended follow-up data from 2 trials confirmed that larotrectinib yielded positive progression-free and overall survival outcomes for patients with NTRK-positive lung cancer.
Amivantamab/Lazertinib/Chemo Regimen Gains Traction in EGFR-Mutant NSCLC
Phase 1 findings showed a 50% overall response rate among patients with EGFR-mutated non–small cell lung cancer who received amivantamab in combination with lazertinib plus carboplatin and pemetrexed.
Tislelizumab Maintains Superior Overall Survival Benefit Vs Docetaxel in Pretreated NSCLC
Patients with previously treated non–small cell lung cancer experienced a median overall survival of 16.9 months with second- or third-line tislelizumab vs 11.9 months with docetaxel.
Neoadjuvant Triplet Regimen Safe, Effective in Patients With Resectable Mesothelioma
Updates from the ongoing S1619 trial suggest that a triplet combination regimen of neoadjuvant cisplatin, pemetrexed, and atezolizumab is effective and tolerable in the treatment of patients with resectable pleural mesothelioma.
Study Identifies High Mortality Rates in Patients with COVID-19 and Malignant Pleural Mesothelioma
Patients with both COVID-19 and malignant pleural mesothelioma showed high rates of hospitalization and mortality.
Modified Monitoring Requirements, Telehealth Increase Lung Cancer Clinical Trial Enrollment in COVID-19 Era
International lung cancer clinical trial sites reported that flexibilities in time and place were effective strategies to mitigate COVID–19-related patient concerns and to increase participation.
Patients Report Improved Outcomes Following Mobocertinib Treatment for NSCLC Subtype
Selectively targeting the EGFR exon insertion mutations was associated with improved outcomes in patients with previously treated non-small cell lung cancer.
Following Reconstruction, Patients With Early Breast Cancer May Safely Opt For a Shorter Course of Radiation Therapy
PVd Confers a Small OS Benefit to Patients With Relapsed/Refractory Multiple Myeloma
2 Clarke Drive Cranbury, NJ 08512